| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | IgG3 |
| Uniprot No | P01860 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-446aa |
| 氨基酸序列 | ASTKGPSVFPLAPCSRSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYTCNVNHKPSNTKVDKRVELKTPLGDTTHTCPRCPEPKSCDTPPPCPRCPEPKSCDTPPPCPRCPEPKSCDTPPPCPRCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVQFKWYVDGVEVHNAKTKPREEQYNSTFRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKTKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESSGQPENNYNTTPPMLDSDGSFFLYSKLTVDKSRWQQGNIFSCSVMHEALHNRFTQKSLSLSPELQLEESCAEAQDGELDGLWTTITIFITLFLLSVCYSATVTFFKVKWIFSSVVDLKQTIIPDYRNMIGQGA |
| 预测分子量 | 49 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于IgG3重组蛋白的参考文献示例(文献信息为虚构示例，仅供参考)：
1. **"Structural and Functional Characterization of Recombinant IgG3 Antibodies"**
- 作者：Smith A, et al.
- 摘要：研究通过哺乳动物细胞表达系统成功制备重组IgG3抗体，分析其与IgG1的结构差异，并证明其更强的补体激活能力及较短的血清半衰期特性。
2. **"IgG3 Fc Engineering Enhances Effector Functions in Cancer Therapy"**
- 作者：Zhang L, et al.
- 摘要：通过Fc区域工程化改造重组IgG3.显著提高其对Fcγ受体的亲和力，在体外和动物模型中显示出优于IgG1的抗肿瘤活性。
3. **"Recombinant IgG3 as a Potent Neutralizer of Viral Pathogens"**
- 作者：Johnson R, et al.
- 摘要：报道重组IgG3在针对包膜病毒的中和实验中表现出高效阻断能力，归因于其延长的铰链区结构增强抗原结合空间灵活性。
4. **"Comparative Pharmacokinetics of IgG Subclasses: Focus on Recombinant IgG3"**
- 作者：Lee H, et al.
- 摘要：系统比较IgG亚类的药代动力学，发现重组IgG3因与FcRn结合能力较弱导致清除速率较快，提示需通过蛋白工程优化其临床适用性。
**注意**：以上文献为示例，实际文献需通过PubMed、Google Scholar等平台检索关键词(如"recombinant IgG3"、"IgG3 engineering")。
**Background of IgG3 Recombinant Protein**
Immunoglobulin G3 (IgG3) is a subclass of IgG antibodies, pivotal in adaptive immune responses. Unlike other IgG subclasses, IgG3 exhibits unique structural and functional properties. Its heavy chain contains an extended hinge region rich in proline and cysteine residues, conferring flexibility and enhanced avidity for antigens. This structural feature also contributes to IgG3’s superior ability to activate complement pathways and engage Fcγ receptors on immune cells, making it highly effective in pathogen neutralization and immune complex clearance.
Recombinant IgG3 production leverages genetic engineering to express and purify IgG3 molecules *in vitro*. This approach enables precise control over antibody design, such as humanization, affinity maturation, or engineering of effector functions. However, IgG3’s long hinge region poses challenges for recombinant expression due to susceptibility to proteolytic degradation and aggregation. Advances in mammalian expression systems (e.g., CHO or HEK293 cells) and protein engineering (e.g., hinge truncation or stabilization) have improved yield and stability.
Functionally, recombinant IgG3 is explored for therapeutic applications, particularly in infectious diseases and oncology, where its potent effector functions may enhance pathogen or tumor cell elimination. It also serves as a research tool to dissect antibody structure-function relationships, especially the role of the hinge region in immune activation. Despite its potential, IgG3’s shorter serum half-life (due to stronger binding to FcRn) compared to IgG1 or IgG4 limits clinical use, prompting studies to optimize pharmacokinetics through Fc modifications.
Current research focuses on balancing IgG3’s robust effector activity with stability and bioavailability, positioning it as a promising candidate for next-generation biologics and tailored immunotherapies.
×
